However, this feature was not found to apply to our combinational therapy regimen (Res + MeV): hepatoma cell–specific expression levels of CD46 were not found to be enhanced by resminostat cotreatment (data not shown). This evidence concerns the gene CD46 and hepatocellular carcinoma.